Cadenza Bio, Inc., a US-based preclinical biotechnology company, announced on Thursday that it has named Michael A Panzara, MD, MPH as its new director.

Dr Panzara brings more than 22 years of biopharmaceutical experience to Cadenza Bio. Currently, he serves as chief medical officer at Neurvati Neurosciences. He has served in key leadership positions at Wave Life Sciences, Sanofi, Genzyme, and Biogen. He also works on the board of directors of Athira Pharma, Inc.

Dr Carol Curtis, Cadenza Bio chief executive officer, said, 'We are delighted to welcome Dr Panzara to our board of directors. His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio. Dr Panzara's strategic insights and deep understanding of the industry will be invaluable as we continue to advance our innovative drug pipeline and work towards bringing transformative treatments to patients in need.'